News

Support for Theravectys
Enlarge image

BusinessFrance

Support for Theravectys

05.09.2012 - French vaccine specialist Theravectys has closed a financing round worth €7.48m. The firm will use cash to develop immunotherapies.

With this new cash in hand, the biotech will continue the development of a new generation of vaccines based on lentiviral vectors. "Within the next two years, we hope to be able to demonstrate in humans not only the safety but also the potential effectiveness of our anti-HIV vaccine candidate," says Renaud Vaillant, CEO of Theravectys. The funds raised stem exclusively from private investors. Among them are prominent representatives from large entities like the Bettencourt family (L'Oréal), Philippe Oddo (Bank Oddo & Cie), Richard Hennessy (Cognac Hennessy) and Guy Paillaud (retail). John Pieters, former CEO of Amgen France completes the syndicate.

In particular, the fresh money enables the company to fund a Phase I/II clinical trial of its anti-HIV vaccine candidate and the development of new vaccine candidates based on lentiviral vectors. Theravectys also plans to move to new laboratories that are larger and can better accommodate the company’s development. Theravectys uses lentiviral vectors which have the ability to induce a strong, sustainable and diversified cellular immune response by endogenously stimulating dendritic cells. This technology was developed at the Institute Pasteur in Paris and out-licensed to Theravectys.

http://www.european-biotechnology-news.com/news/news/2012-03/prominent-support-for-theravectys.html

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

Events

All Events

Current issue

All issues

Product of the week

Products